Da An Gene adjusts investments, bolsters governance, and boosts liquidity

Da An Gene of Sun Yat-Sen University announced a provision for asset impairment totaling CNY 17,996.74m for the first three quarters of 2025, primarily from credit impairment losses (CNY 17,230.14m) and asset impairment losses (CNY 766.60m). This adjustment will reduce net profit attributable to shareholders by CNY 15,403.77m. Concurrently, the company is optimizing its asset structure by authorizing the sale of a portion of its stock assets to enhance liquidity.

The company is also refining its cash management strategy by adjusting its idle own funds cash management products. The previous plan to purchase principal-protected wealth management products or deposit-type products (up to CNY 2.5bn with a term of no more than 3 years) is updated to include low-risk (R1) wealth management products. This aims to improve yield while maintaining safety and liquidity.

Furthermore, Da An Gene is strengthening its corporate governance by expanding its board of directors from nine to eleven members, including an additional independent director and an employee director. Liu Huanliang has been nominated as a new independent director. Several internal policies, including those on independent directors, fundraising management, external guarantees, related party transactions, and auditor selection, are being revised to enhance operational compliance.